– USA, IL – Eton Pharmaceuticals, Inc. today announced it has appointed Paul V. Maier to its Board of Directors.
“We are excited to have Paul join Eton’s board and Chair our Audit Committee. His extensive financial leadership experience within the pharmaceutical industry will be a valuable asset to Eton,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. Maier added, “I look forward to working with the seasoned Eton board and management team in building a successful commercial entity by bringing innovative and cost-effective products to market.”
Paul V. Maier currently serves as a financial advisor to the life science industry. Mr. Maier is the former CFO of Sequenom, Inc. and Ligand Pharmaceuticals Inc. and has over 25 years experience as a senior executive in biotechnology and specialty pharmaceutical companies. Mr. Maier has served on the boards of eight companies and currently serves as Audit Committee Chair on four public life science companies. Mr. Maier received an M.B.A from Harvard Business School and a B.S. from Pennsylvania State University. Mr. Maier is also an Executive Partner at the College of William & Mary Mason School of Business.
About Eton:
Eton Pharmaceuticals, Inc., a privately held company, is focused on the development and commercialization of innovative sterile product candidates utilizing the FDA 505(b)(2) regulatory pathway. The Eton leadership team has a history of success in developing and commercializing sterile injectable pharmaceutical products. Eton is currently developing a broad portfolio of essential branded products and expects to file products within the US during 2018.
For more information : http://www.etonpharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
